Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA, Branch RA (1987) Cancer Res 47: 5488-93 Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA (1990) Clin Pharmacol Ther 48: 286-95 Lung tumor resection does not affect debrisoquine metabolism. Shaw GL, Falk RT, Deslauriers J, Nesbitt JC, McKneally MF, Frame JN, Feld R, Issaq HJ, Ruckdeschel JC, Hoover RN (1994) Cancer Epidemiol Biomarkers Prev 3: 141-4 Debrisoquine metabolism and lung cancer risk. Shaw GL, Falk RT, Deslauriers J, Frame JN, Nesbitt JC, Pass HI, Issaq HJ, Hoover RN, Tucker MA (1995) Cancer Epidemiol Biomarkers Prev 4: 41-8 Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Anthony LB, Boeve TJ, Hande KR (1995) Cancer Chemother Pharmacol 36: 125-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.